AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$CERS

Cerus (CERS) Q3 2026 Earnings Call Transcript

Cerus (CERS) reported Q3 2026 earnings, highlighting 10% year-over-year revenue growth, 12% North American sales increase, and positive adjusted EBITDA for the 10th consecutive quarter. Key achievements include positive Phase III REDeS study results for red blood cell transfusion technology, strong ISC franchise performance, and international INT200 illuminator rollout. The company aims for sustained double-digit growth and financial strength.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 10:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 10:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cerus (CERS) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CERSBullishHigh
01

Why it matters

The trial success adds a new revenue stream and may drive near‑term stock appreciation.

02

Market read

First disclosure of pivotal trial data; material for investors and may trigger price movement.

03

What to watch

Potential competition from alternative pathogen‑reduction technologies.

Relevance 8/10Novelty 9/10Timing: today

Background

Cerus held its Q3 2026 earnings call, highlighting a 10% YoY revenue rise and announcing positive Phase III REDeS trial results for red‑cell applications.

Company-level read

Ticker impact

$CERSBullishHigh confidence
Context

Cerus reported positive top‑line Phase III REDeS trial results and Q3 2026 earnings, indicating new product approval potential.

Expected impact

likely upside as market absorbs the trial success

Evidence & confidence

Phase III success is a material catalyst for a biotech; no prior public disclosure of these results.

Market effects

Sector

Positive data could boost the broader blood‑product pathogen‑reduction sector.

Regional

U.S. and European markets may see modest gains in biotech indices.

Global

Limited to biotech investors; no broad macro impact.

Counterpoint

What could challenge this read

If regulatory review stalls, the rally could be short‑lived.

Key entities

  • company
    Cerus Corporation

    US‑listed biotech developing INTERCEPT pathogen‑reduction technology.

Read at source← All news

StoryCerus posts 10% Q3 product revenue growth and reaffirms 2026 guidance

Also covered by

3 outlets

Related articles

NOV 3
$CERSMed

Cerus Corp (CERS) Q3 2026 Earnings Call Highlights: Revenue Climbs 10% as Adjusted

Cerus Corp (CERS) reported a 10% revenue increase in Q3 2026, but faced headwinds from geopolitical conflicts and a strong US dollar. Product gross margin declined to 52.4% due to foreign exchange and inflation. Government contract revenue fell to $6.3M. CEO Vivek Jayaraman discussed delays in regulatory approvals, international market challenges, and growth drivers like the BCA agreement. The company expects CE-mark clearance for red blood cell technology in late 2027 and is working on Gen.

finance.yahoo.com3 min
NOV 3
$CERSHighAI 9/10

Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells

Cerus Corporation (CERS) reported positive Phase 3 RedeS trial results for its INTERCEPT Blood System for Red Blood Cells, meeting primary efficacy and safety endpoints. The study showed non-inferiority of INTERCEPT RBCs compared to conventional RBCs, with no significant safety differences. Full results will be submitted for publication and presented at scientific meetings. The FDA has not yet reviewed the final study report.

biospace.com2 min
NOV 3
$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

finance.yahoo.com2 min
NOV 2
$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

finance.yahoo.com1 min